{"DataElement":{"publicId":"7153882","version":"1","preferredName":"IWG-MRT Myelofibrosis Molecular Response Best Outcome of TherapyType","preferredDefinition":"A description of the best IWG-MRT myelofibrosis molecular response to therapy.","longName":"7153845v1.0:7153866v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"7153845","version":"1","preferredName":"IWG-MRT Myelofibrosis Molecular Response Best Outcome of Therapy","preferredDefinition":"Molecular response evaluation must be analyzed in peripheral blood granulocytes and requires confirmation by repeat testing within 6 months window. Complete response: Eradication of a pre-existing abnormality. Partial response: greater than or equal to 50 percent decrease in allele burden (partial response applies only to patients with at least 20 percent mutant allele burden at baseline.) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)_Having the most positive qualities._The result of therapy for a given disease or condition in a patient or group of patients.","longName":"7158682v1.0:3194600v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"7158682","version":"1","preferredName":"IWG-MRT Myelofibrosis Molecular Remission","preferredDefinition":"Molecular response evaluation must be analyzed in peripheral blood granulocytes and requires confirmation by repeat testing within 6 months window. Complete response: Eradication of a pre-existing abnormality. Partial response: greater than or equal to 50 percent decrease in allele burden (partial response applies only to patients with at least 20 percent mutant allele burden at baseline.) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","longName":"C168653","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IWG-MRT Myelofibrosis Molecular Remission","conceptCode":"C168653","definition":"Molecular response evaluation must be analyzed in peripheral blood granulocytes and requires confirmation by repeat testing within 6 months window. Complete response: Eradication of a pre-existing abnormality. Partial response: greater than or equal to 50 percent decrease in allele burden (partial response applies only to patients with at least 20 percent mutant allele burden at baseline.) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DB2D1A8-3A1C-34ED-E053-F662850A91CA","latestVersionIndicator":"Yes","beginDate":"2020-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-02-03","modifiedBy":"ONEDATA","dateModified":"2020-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3194600","version":"1","preferredName":"Best Outcome of Therapy","preferredDefinition":"Having the most positive qualities.:The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C25432:C18919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D80CD45-BE7A-5B19-E040-BB89AD430E80","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-03-02","modifiedBy":"ONEDATA","dateModified":"2011-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D33A592-B6FC-49C0-E053-F662850A5742","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"MALUMK","dateModified":"2020-05-11","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7153866","version":"1","preferredName":"IWG-MRT Myelofibrosis Molecular Response Type","preferredDefinition":"Molecular response evaluation must be analyzed in peripheral blood granulocytes and requires confirmation by repeat testing within 6 months window. Complete response: Eradication of a pre-existing abnormality. Partial response: greater than or equal to 50 percent decrease in allele burden (partial response applies only to patients with at least 20 percent mutant allele burden at baseline.) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)_Something distinguishable as an identifiable class based on common qualities.","longName":"7153866v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Re-emergence of a pre-existing molecular abnormality","valueDescription":"Appearance Pre-existing Molecular Abnormality","ValueMeaning":{"publicId":"7153867","version":"1","preferredName":"Appearance Pre-existing Molecular Abnormality","longName":"7153867","preferredDefinition":"The outward or visible aspect of a person or thing.: Having been present before a specific date or event.: A molecular or cytogenic abnormality which occurs in either human disease states or disease models.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Appearance","conceptCode":"C25377","definition":"The outward or visible aspect of a person or thing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pre-existing","conceptCode":"C73621","definition":"Having been present before a specific date or event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Molecular Abnormality","conceptCode":"C3910","definition":"A molecular or cytogenetic abnormality which occurs in either human disease states or disease models.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D33FBFD-A2ED-6275-E053-F662850A9B79","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D33FBFD-A306-6275-E053-F662850A9B79","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"},{"value":"Partial response (PR)","valueDescription":"Partial response","ValueMeaning":{"publicId":"7153868","version":"1","preferredName":"Partial response","longName":"7153868","preferredDefinition":"Greater than or equal to 50% decrease in allele burden.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D33FBFD-A310-6275-E053-F662850A9B79","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D33FBFD-A328-6275-E053-F662850A9B79","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"},{"value":"None of the above","valueDescription":"None of the above","ValueMeaning":{"publicId":"7153853","version":"1","preferredName":"None of the above","longName":"7153853","preferredDefinition":"Does not meet the CR or PR criteria.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D26BCD7-0528-5524-E053-F662850ACB41","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D33FBFD-A333-6275-E053-F662850A9B79","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5043360","version":"1","preferredName":"Not Applicable","longName":"5043360","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2421E11B-65A6-151D-E050-BB89AD4378BB","latestVersionIndicator":"Yes","beginDate":"2015-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-09","modifiedBy":"DWARZEL","dateModified":"2018-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D33FBFD-A33D-6275-E053-F662850A9B79","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"},{"value":"Not assessed","valueDescription":"NOT ASSESSED","ValueMeaning":{"publicId":"2559594","version":"1","preferredName":"NOT ASSESSED","longName":"2559594","preferredDefinition":"Indicates that an assessment was not performed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Assessed","conceptCode":"C139527","definition":"Indicates that an assessment was not performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D33FBFD-A347-6275-E053-F662850A9B79","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"},{"value":"Complete response (CR)","valueDescription":"Complete response","ValueMeaning":{"publicId":"7153856","version":"1","preferredName":"Complete response","longName":"7153856","preferredDefinition":"Eradication of pre-existing abnormality.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D26BCD7-05A9-5524-E053-F662850ACB41","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"KUMMEROA","dateModified":"2020-01-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D355673-14B9-51B7-E053-F662850A1E02","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7158683","version":"1","preferredName":"IWG-MRT Myelofibrosis Molecular Remission Type","preferredDefinition":"Molecular response evaluation must be analyzed in peripheral blood granulocytes and requires confirmation by repeat testing within 6 months window. Complete response: Eradication of a pre-existing abnormality. Partial response: greater than or equal to 50 percent decrease in allele burden (partial response applies only to patients with at least 20 percent mutant allele burden at baseline.) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8):Something distinguishable as an identifiable class based on common qualities.","longName":"C168653:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IWG-MRT Myelofibrosis Molecular Remission","conceptCode":"C168653","definition":"Molecular response evaluation must be analyzed in peripheral blood granulocytes and requires confirmation by repeat testing within 6 months window. Complete response: Eradication of a pre-existing abnormality. Partial response: greater than or equal to 50 percent decrease in allele burden (partial response applies only to patients with at least 20 percent mutant allele burden at baseline.) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DB3387A-D4CB-5342-E053-F662850AC8E3","latestVersionIndicator":"Yes","beginDate":"2020-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-02-03","modifiedBy":"ONEDATA","dateModified":"2020-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D33FBFD-A2D3-6275-E053-F662850A9B79","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"MALUMK","dateModified":"2020-11-11","changeDescription":".Released 11/11/2020 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What was the best IWG-MRT mye","type":"Preferred Question Text","description":"What was the best IWG-MRT myelofibrosis molecular response to therapy?","url":null,"context":"NHLBI"},{"name":"Specify the best molecular response to line of therapy","type":"Alternate Question Text","description":"Specify the best molecular response to line of therapy","url":null,"context":"NHLBI"},{"name":"Specify the best molecular response to line of therapy","type":"Application Standard Question Text","description":"Specify the best molecular response to line of therapy","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D34310A-28C4-0472-E053-F662850AE13B","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"KUMMEROA","dateModified":"2020-12-21","changeDescription":".2020-12-21 ak OK to release per WZ. System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}